The antiphospholipid syndrome (APS) is characterised by thrombosis and recurrent fetal loss accompanied by the presence of lupus anticoagulant (LA) and/or anti-cardiolipin antibodies (aCLA).1 2 Anti-phospholipid (aPL) antibodies require a protein cofactor, β₂-glycoprotein 1 (β₂-GP1) or prothrombin, for proper binding.3^–5 Patients may also present with antibodies to β₂-GP1, but not LA or aCLA. Originally, they were classified as having the anti-phospholipid/cofactor syndrome,6 7 but recently the Sapporo classification criteria have been updated by including the β₂-GP1-antibodies.8

We retrospectively evaluated the clinical manifestations of APS in 105 consecutive patients that presented with the suspicion of APS and/or …